Bill & Melinda Gates Foundation - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH268469D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

September 2018

Total pages

74

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

Bill & Melinda Gates Foundation (BMGF), formerly William H. Gates Foundation is a provider of health development programs. The foundation concentrates on improving healthcare, decrease poverty in America and provides access to information equipment. It offers global health services in the fields of discovery and translational sciences, enteric and diarrheal diseases, HIV, malaria, neglected infectious diseases, and tuberculosis services. BMGF's global development services include agricultural development, family planning, emergency response, financial services for the poor, nutrition fulfillment, vaccine delivery, and water, sanitation and hygiene services. The foundation has its presence in Asia, Africa, Europe, North America, South America, and Oceania. BMGF is headquartered in Seattle, Washington, the US.

Bill & Melinda Gates Foundation-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

Bill & Melinda Gates Foundation, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Bill & Melinda Gates Foundation, Medical Devices Deals, 2012 to YTD 2018 10

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deal Details 15

Venture Financing 15

Evolve BioSystems Raises USD40 Million in Series C Financing 15

Visterra Raises Additional USD23.6 Million in Series C Financing 17

Arsanis Raises USD45.5 Million in Series D Financing 19

Vir Biotech Raises Funds through Venture Financing 21

Kymab Raises USD100.5 Million in Series C Financing 22

Just Biotherapeutics Raises USD14 Million in Series A2 Financing 24

Affinivax Raises USD2.5 Million in Venture Financing 26

Lodo Therapeutics Raises USD17 Million in Series A Financing 27

Atreca Raises USD56 Million in Series A Financing 29

CureVac to Raise USD76 Million in Venture Financing 30

Affinivax Raises USD4 Million in Seed Venture Financing 31

Synlogic Raises Additional USD5 Million in Series A Venture Financing 32

Kymab Raises USD40 Million in Series B Financing 33

Visterra Raises USD 8.1 Million In Extended Series A Financing 34

Visterra Raises Additional USD 13 Million In Series A Financing 36

Genocea Biosciences Raises USD 30 Million In Series C Financing 38

Partnerships 40

Novartis and Bill & Melinda Gates Foundation Enter into Partnership 40

CureVac to Enter into Development Agreement with Bill & Melinda Gates 41

Sanofi Pasteur Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 42

GSK Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 43

Anacor Pharma Amends Research Agreement With Bill & Melinda Gates Foundation 44

Atreca Enters into Agreement with Bill & Melinda Gates Foundation 45

Equity Offering 46

Achaogen to Raise USD10 Million in Private Placement of Shares 46

Intarcia Therapeutics Raises USD206 Million in Second Tranche of Private Placement of Shares 47

CureVac Raises USD110 Million in Private Placement of Shares 48

Bill & Melinda Gates Foundation-Key Competitors 49

Bill & Melinda Gates Foundation-Key Employees 50

Bill & Melinda Gates Foundation-Locations And Subsidiaries 51

Head Office 51

Other Locations & Subsidiaries 51

Joint Venture 51

Recent Developments 53

Government and Public Interest 53

Aug 03, 2018: HitGen launching initiative to discover new medicines to combat tuberculosis and malaria 53

Jun 28, 2018: SwRI receives grant to reduce the cost of current malaria treatment 54

Jun 06, 2018: Latest Gates Foundation grants will advance research on educational inclusion and global immunization 55

May 16, 2018: Molecular Health to pursue drug repurposing in tuberculosis treatment and perinatal complications 56

May 15, 2018: Aiming Low: Landmark study optimises steroid use in pregnancy 57

Apr 27, 2018: Sabin Vaccine Institute Issues Statement on New Universal Flu Vaccine Development Grand Challenge 58

Feb 13, 2018: CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria 59

Feb 12, 2018: Inovio and The Wistar Institute Receive More Than USD 4.6 Million in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria 60

Dec 13, 2017: Sirenas Receives Research Grant Totaling USD 1.68 M To Accelerate Its Drug Discovery Technology, ATLANTIS 61

Nov 29, 2017: Phyton Biotech Wins Grant to Develop New Approaches to Manufacturing Artemisinin 62

Nov 09, 2017: PeptiDream Receives Grant to Discover and Develop Novel Therapeutics for Infectious Disease 63

Oct 23, 2017: Ventria Bioscience aids global fight against intestinal infections that threaten up to 400 million children a year 64

Sep 08, 2017: Malaria: Drug Candidate May Reduce Spread of the Parasite 65

Aug 18, 2017: IHI Partners with South Africa National Department of Health on Initiative to Improve Tuberculosis Care and Outcomes 67

Jun 12, 2017: Rotary and the Bill & Melinda Gates Foundation announce USD 450 million commitment to end polio 68

Mar 06, 2017: Vaxess Technologies Receives Grants Totaling USD 6 Million to Develop Microneedle Vaccines for Polio, Measles, Rubella 69

Jan 09, 2017: Kymab expands Infectious Disease Programmes 70

Other Significant Developments 71

Mar 28, 2018: As the GHIT Fund Closes Out First Five Years of R&D for Lifesaving Medical Breakthroughs, It Launches Next Phase, Focusing on Access and Delivery, Bringing Total Investment to 13.2 Billion Yen (USD 123 Million) 71

Appendix 74

Methodology 74

About GlobalData 74

Contact Us 74

Disclaimer 74


List of Figure

List of Figures

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Bill & Melinda Gates Foundation, Medical Devices Deals, 2012 to YTD 2018 10


List of Table

List of Tables

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Key Facts 2

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Bill & Melinda Gates Foundation, Deals By Therapy Area, 2012 to YTD 2018 9

Bill & Melinda Gates Foundation, Medical Devices Deals, 2012 to YTD 2018 10

Bill & Melinda Gates Foundation, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Evolve BioSystems Raises USD40 Million in Series C Financing 15

Visterra Raises Additional USD23.6 Million in Series C Financing 17

Arsanis Raises USD45.5 Million in Series D Financing 19

Vir Biotech Raises Funds through Venture Financing 21

Kymab Raises USD100.5 Million in Series C Financing 22

Just Biotherapeutics Raises USD14 Million in Series A2 Financing 24

Affinivax Raises USD2.5 Million in Venture Financing 26

Lodo Therapeutics Raises USD17 Million in Series A Financing 27

Atreca Raises USD56 Million in Series A Financing 29

CureVac to Raise USD76 Million in Venture Financing 30

Affinivax Raises USD4 Million in Seed Venture Financing 31

Synlogic Raises Additional USD5 Million in Series A Venture Financing 32

Kymab Raises USD40 Million in Series B Financing 33

Visterra Raises USD 8.1 Million In Extended Series A Financing 34

Visterra Raises Additional USD 13 Million In Series A Financing 36

Genocea Biosciences Raises USD 30 Million In Series C Financing 38

Novartis and Bill & Melinda Gates Foundation Enter into Partnership 40

CureVac to Enter into Development Agreement with Bill & Melinda Gates 41

Sanofi Pasteur Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 42

GSK Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 43

Anacor Pharma Amends Research Agreement With Bill & Melinda Gates Foundation 44

Atreca Enters into Agreement with Bill & Melinda Gates Foundation 45

Achaogen to Raise USD10 Million in Private Placement of Shares 46

Intarcia Therapeutics Raises USD206 Million in Second Tranche of Private Placement of Shares 47

CureVac Raises USD110 Million in Private Placement of Shares 48

Bill & Melinda Gates Foundation, Key Competitors 49

Bill & Melinda Gates Foundation, Key Employees 50

Bill & Melinda Gates Foundation, Other Locations 51

Bill & Melinda Gates Foundation, Subsidiaries 51

Bill & Melinda Gates Foundation, Joint Venture 51

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022